https://www.selleckchem.com/pr....oducts/geldanamycin.
Extensive clinical, biological, and imaging data will be recorded during a 3-yr follow-up. EXPECTED OUTCOMES Discovering to improve the efficiency of UIA follow-up by identifying additional clinical, imaging, biological, and anatomic risk factors of UIA growth. DISCUSSION A prospective nationwide recruitment allows for the inclusion of a large cohort of patients with UIA. It will combine clinical phenotyping and specific imaging with AWE screening. It will enable to exploit metadata and to explore some pathophysiological pathways b